[go: up one dir, main page]

PT96994A - Metodo para purificacao de hiv gp12o, de forma a proporcionar um glicopeptido - Google Patents

Metodo para purificacao de hiv gp12o, de forma a proporcionar um glicopeptido

Info

Publication number
PT96994A
PT96994A PT96994A PT9699491A PT96994A PT 96994 A PT96994 A PT 96994A PT 96994 A PT96994 A PT 96994A PT 9699491 A PT9699491 A PT 9699491A PT 96994 A PT96994 A PT 96994A
Authority
PT
Portugal
Prior art keywords
protein
hiv
binding affinity
glycopeptide
substantially identical
Prior art date
Application number
PT96994A
Other languages
English (en)
Other versions
PT96994B (pt
Inventor
Nancy L Haighwood
Carl Scandella
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23949786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT96994(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of PT96994A publication Critical patent/PT96994A/pt
Publication of PT96994B publication Critical patent/PT96994B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Table Devices Or Equipment (AREA)
  • Cookers (AREA)
  • Gloves (AREA)
PT96994A 1990-03-09 1991-03-08 Metodo para purificacao da gp12o de hiv, de forma a proporcionar um glicopeptido PT96994B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49085890A 1990-03-09 1990-03-09

Publications (2)

Publication Number Publication Date
PT96994A true PT96994A (pt) 1991-10-31
PT96994B PT96994B (pt) 1998-07-31

Family

ID=23949786

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96994A PT96994B (pt) 1990-03-09 1991-03-08 Metodo para purificacao da gp12o de hiv, de forma a proporcionar um glicopeptido

Country Status (8)

Country Link
EP (1) EP0519001B2 (pt)
JP (2) JP2624894B2 (pt)
AT (1) ATE207930T1 (pt)
CA (1) CA2077753C (pt)
DE (1) DE69132795T3 (pt)
IE (1) IE910779A1 (pt)
PT (1) PT96994B (pt)
WO (1) WO1991013906A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE910779A1 (en) * 1990-03-09 1991-09-11 Chiron Corp PURIFIED gp120 COMPOSITION RETAINING NATURAL CONFORMATION
US7041293B1 (en) 1990-04-03 2006-05-09 Genentech, Inc. HIV env antibodies
ATE125157T1 (de) * 1990-04-03 1995-08-15 Genentech Inc Methoden und zusammensetzungen zur impfung gegen hiv.
DE4400659C2 (de) † 1993-01-16 1995-07-27 Manfred Dr Schawaller Verfahren zur Gewinnung nativer Domänen viraler Membranproteine, deren Verwendung, insbesondere als Impfstoff gegen HIV, sowie diese nativen Domänen viraler Membranproteine selbst
NZ267838A (en) * 1993-06-07 1997-12-19 Genentech Inc Preparation of an hiv gp 120 subunit vaccine involving determining a neutralising epitope in the v2 and/or c4 domains
WO1995025789A1 (en) * 1994-03-22 1995-09-28 The Immune Response Corporation Highly efficient production and isolation of viral particles
KR100374308B1 (ko) * 1995-07-27 2003-12-18 주식회사 엘지생명과학 재조합차이니스햄스터오바리세포로부터발현된수두바이러스의지피i당단백질의정제방법
US6585979B1 (en) 1996-07-08 2003-07-01 Genentech, Inc. HIV envelope polypeptides and immunogenic composition
EP1980617A1 (en) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
PT1141315E (pt) 1998-12-31 2008-05-05 Novartis Vaccines & Diagnostic Polipéptidos do envelope (env) de hiv modificados
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7556814B2 (en) * 2003-10-23 2009-07-07 Karp Nelson M Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane
EP1783138A4 (en) * 2004-07-27 2007-08-22 Genomidea Inc PROCESS FOR PURIFYING A VIRUS ENVELOPE

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01120284A (ja) * 1987-11-05 1989-05-12 Shiro Kato Ｈｉｖ不完全粒子および該製造方法
IE910779A1 (en) * 1990-03-09 1991-09-11 Chiron Corp PURIFIED gp120 COMPOSITION RETAINING NATURAL CONFORMATION

Also Published As

Publication number Publication date
CA2077753C (en) 2000-02-29
DE69132795T2 (de) 2002-06-20
PT96994B (pt) 1998-07-31
WO1991013906A1 (en) 1991-09-19
EP0519001B2 (en) 2007-12-19
JP2624894B2 (ja) 1997-06-25
JPH05505616A (ja) 1993-08-19
DE69132795T3 (de) 2008-07-10
DE69132795D1 (de) 2001-12-13
EP0519001B1 (en) 2001-10-31
EP0519001A1 (en) 1992-12-23
IE910779A1 (en) 1991-09-11
JPH09227588A (ja) 1997-09-02
ATE207930T1 (de) 2001-11-15
CA2077753A1 (en) 1991-09-10

Similar Documents

Publication Publication Date Title
PT96994A (pt) Metodo para purificacao de hiv gp12o, de forma a proporcionar um glicopeptido
Furthmayr et al. Fractionation of the major sialoglycopeptides of the human red blood cell membrane
DK0458841T3 (da) Fremgangsmåde til anvendelse og fremstilling af peptider
MX9603637A (es) Purificacion de anticuerpo.
ES2146600T3 (es) Condroitinasa, procedimiento para su preparacion y composicion farmaceutica.
ES2188665T3 (es) Procedimiento para la preparacion de fragmentos de cardiodilatina, fragmentos de cardiodilatina muy purificados y productos intermedios para su preparacion.
ATE425989T1 (de) Proteinreinigungsverfahren
ES2155477T3 (es) Purificacion cromatografica y procedimiento de separacion de acidos nucleicos.
RU93046317A (ru) Хиндроитиназа, способ ее получения и содержание ее фармацевтические композиции
SE8402861L (sv) Rening av biologiskt material
CA1133898A (en) Purification of interferon
ES2058538T3 (es) Compuestos de proteina a purificados y procedimiento para su preparacion.
CN1089609C (zh) 从人血浆分部分离过程产生的馏分中回收免疫球蛋白的方法
DK0646594T3 (da) Fremgangsmåde til rensning af proteiner
DK0402205T3 (da) Fremgangsmåde til fremstilling af oprensede albuminopløsninger
PT98669A (pt) Processo para a preparacao da estrutura proteica da toxina de gelonina vegetal
ATE509028T1 (de) Ionen-austausch-chromatographische trennung von glp-1 und verwandten peptiden
JP2004512539A (ja) 複合分離法
Piggot et al. Cyanogen bromide cleavage and partial sequence of the heavy chain of a pathological immunoglobulin G
DE3782771D1 (de) Gegen pseudomonas aeruginosa infektionen wirksame praeparationen und verfahren zu ihrer herstellung.
EP0117470B1 (en) Process for producing interferon (ifn-gamma) subtypes 26k and 21k
Kobayashi et al. Improved procedure for the isolation of J-chain from human polymeric immunoglobulins
Becker et al. Cyanogen bromide peptides of the rabbit collagen a1-chain
KR900003095B1 (ko) 신규 thf 조성물의 제조방법
ATE81471T1 (de) Polydisperse native pseudomonas-flagella(h)antigene (fag) und verfahren zu ihrer gewinnung.

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19910710

FG3A Patent granted, date of granting

Effective date: 19980414

PD4A Change of proprietorship

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC., US

Effective date: 20080215

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20130415